Most bought healthcare stocks in Q3 2022

See which Healthcare stocks institutional investors increased the most in Q3 2022, measured as net growth in reported share positions from Q2 2022 into Q3 2022. Notable additions at the top of this list include HALEON PLC-ADR (HLN), GSK PLC-SPON ADR (GSK), TREVI THERAPEUTICS INC (TRVI), AVANTOR INC (AVTR). These rankings are based on SEC 13F filings from the investors we track.

SymbolNameNet sharesNet valueNewAddedTrimmedSold outHolding now
HLNHALEON PLC-ADR78,077,591$9.25M60006
GSKGSK PLC-SPON ADR68,326,525$2.01M50106
TRVITREVI THERAPEUTICS INC4,667,687$7.00K11002
AVTRAVANTOR INC4,331,571-$72.70K13105
ELANELANCO ANIMAL HEALTH INC3,856,580-$339.33K12104
ABTABBOTT LABORATORIES3,579,673$94.21K11409
BFLYBUTTERFLY NETWORK INC2,699,255$26.29K01102
EXASEXACT SCIENCES CORP2,651,137-$173.18K11002
CLOVCLOVER HEALTH INVESTMENTS CO2,351,160$3.28K01001
AGLAGILON HEALTH INC2,241,834$63.93K01011
PFEPFIZER INC2,149,528-$9.35M128111
NEOGNEOGEN CORP1,875,804$21.37K11002
CYHCOMMUNITY HEALTH SYSTEMS INC1,795,038$3.06K11002
SIGASIGA TECHNOLOGIES INC1,715,736$16.86K01001
ILMNILLUMINA INC1,715,327$346.07K02012
EWTXEDGEWISE THERAPEUTICS INC1,707,597$21.99K02002
CDNACAREDX INC1,649,060-$9.39K02103
AKBAAKEBIA THERAPEUTICS INC1,534,127$43101001
SENSSENSEONICS HOLDINGS INC1,285,888$1.87K01001
APLSAPELLIS PHARMACEUTICALS INC1,277,554$87.26K20002
CPRXCATALYST PHARMACEUTICALS INC1,194,900$21.33K01001
ELVELEVANCE HEALTH INC1,123,687$289.11K127111
VERVVERVE THERAPEUTICS INC1,048,535$80.99K01011
TXG10X GENOMICS INC-CLASS A973,528-$54.10K01001
BBIOBRIDGEBIO PHARMA INC953,500$32.73K01002
VIRVIR BIOTECHNOLOGY INC950,094$14.84K01001
NVAXNOVAVAX INC880,583$16.03K10001
SDGRSCHRODINGER INC821,535$7.68K02003
XRAYDENTSPLY SIRONA INC820,376-$49.34K12003
CHRSCOHERUS BIOSCIENCES INC733,375$8.12K01102
FATEFATE THERAPEUTICS INC719,697$8.21K11002
ORGOORGANOGENESIS HOLDINGS INC710,800$1.53K01001
MNKDMANNKIND CORP683,450$1.60K01001
MREOMEREO BIOPHARMA GROUP PL-ADR624,705$38001001
LLYELI LILLY & CO585,438$188.42K01305
HCATHEALTH CATALYST INC578,713$4.13K12003
EHABENHABIT INC563,041$7.91K30003
ADPTADAPTIVE BIOTECHNOLOGIES534,901-$31.90K01103
PACBPACIFIC BIOSCIENCES OF CALIF532,764$8.16K01011
CMPSCOMPASS PATHWAYS PLC514,642$5.51K11002
SRPTSAREPTA THERAPEUTICS INC490,900$68.26K01001
SGRYSURGERY PARTNERS INC485,912$1.54K02002
LXRXLEXICON PHARMACEUTICALS INC481,375$1.16K10001
ASRTASSERTIO HOLDINGS INC470,446$56702002
NRIXNURIX THERAPEUTICS INC462,697$8.36K01102
MYGNMYRIAD GENETICS INC454,277$10.48K02002
BCRXBIOCRYST PHARMACEUTICALS INC438,900$5.79K01001
ACHCACADIA HEALTHCARE CO INC417,023$75.53K11204
IARTINTEGRA LIFESCIENCES HOLDING415,913$10.11K02002
TWSTTWIST BIOSCIENCE CORP409,187$21.94K01001
20 symbols with net change in reported shares from tracked managers.0.0021.5M42.9M64.4M85.9MNet change in reported shares (tracked managers)HLNGSKTRVIAVTRELANABTBFLYEXASCLOVAGLPFENEOGCYHSIGAILMNEWTXCDNAAKBASENSAPLSSymbol

Frequently asked questions about Most bought healthcare stocks in Q3 2022

  • What are the most bought Healthcare stocks in Q3 2022?

    The most bought healthcare stocks in Q3 2022 are those with the largest increase in reported share counts across tracked institutional investors compared to Q2 2022, based on SEC 13F filings.

  • Which healthcare stocks did institutional investors added to the most in Q3 2022?

    Among the managers we track, net additions were largest in companies such as HALEON PLC-ADR (HLN), GSK PLC-SPON ADR (GSK), TREVI THERAPEUTICS INC (TRVI), based on aggregated 13F data.

  • How is institutional buying calculated?

    Buying is calculated by summing the net increase in shares reported by tracked investors between two consecutive quarterly 13F snapshots (compared to Q2 2022).

  • Does this include all institutional owners?

    These rankings are based on a subset of tracked institutional investors who file SEC 13F reports. While not exhaustive, the dataset includes many of the largest and most influential funds.

  • Are these trades real-time?

    No. 13F filings are reported quarterly and may be delayed by up to 45 days. The data reflects positions at the end of the reporting period, not real-time trading activity.